# Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1%

> **NCT04329403** · PHASE3 · WITHDRAWN · sponsor: **Aurobindo Pharma Ltd**

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Adapalene 0.1% Gel
- **DRUG:** Differin 0.1% Topical Gel
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04329403
- **Lead sponsor:** Aurobindo Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07
- **Primary completion:** 2021-01
- **Final completion:** 2021-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Market reasons
- **Last updated:** 2020-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04329403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04329403, "Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1%". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04329403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*